Company Overview and News

 
D-Street Buzz: PSU banks drag as BoB falls 2%; Weak rupee helps IT stocks gain led by Mindtree

2018-09-17 moneycontrol
The Indian stock market are trading on a weak note this Monday morning with the Nifty50 down 110 points and is trading at 11,404 while the Sensex is trading lower by 361 points at 37,729.
IOC 500325 500820 500547 533271 RELIANCE TCHQY 532538 ASHOKA 532755 ASIANPAINT 535789 505200 532461 INOXWIND RIGD UCLQY JSL EICHERMOT UNIVCABLES RLNIY 504212 SBAZ ECQRY UBNC BPCL 532508 IDKQY CANFINHOME UCLQF 511196 530965 ULTRACEMCO TECHM IBULHSGFIN PNJZY BRQPY PNB HINDPETRO 500104 539083

 
Inox Wind Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INOXWIND 539083

 
Inox Wind rises 10% as company turned profitable in Q1

2018-08-08 moneycontrol
Share price of Inox Wind rose 10 percent in the early trade on Wednesday as company turned profitable in the quarter ended June 2018.
INOXWIND 539083

 
What Suzlon’s flip-flop on growth guidance tells us about wind sector

2018-08-08 livemint
Wind power provider Suzlon Energy Ltd’s decision to withdraw the annual growth guidance barely three months into the fiscal year triggered a sell-off in its stock on Monday. In May, Suzlon predicted 45-56% revenue growth for the current fiscal year on the basis of its order book and execution capabilities. However, it recently withdrew the growth guidance citing approval delays, prolonged execution cycles and bid deferrals.
SUZLON INOXWIND 532667 SUEL 539083

 
Inox Wind posts Rs 10 crore net profit for Q1

2018-08-07 moneycontrol
Wind power solutions provider Inox Wind today reported a consolidated net profit of Rs 10 crore in the quarter ended on June 30 on the back of higher revenues.
INOXWIND 539083

 
Inox Wind Limited - Outcome of Board Meeting

2018-08-07 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INOXWIND 539083

 
Inox Wind Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INOXWIND 539083

1
 
Inox Wind Limited - Shareholders meeting

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INOXWIND 539083

 
Inox Wind Limited - Shareholders meeting

2018-07-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INOXWIND 539083

 
Inox Wind Limited - Shareholders meeting

2018-07-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
INOXWIND 539083

 
American Superconductor: Where To Now?

2018-07-11 seekingalpha
The Sinovel settlement of $58M is disappointing, but the commercial prospects of the grid segment remain unchanged.
REG HTS INOXWIND AMSC 539083

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...